Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
about
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsNSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisPTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationBioorthogonal small molecule imaging agents allow single-cell imaging of METSimultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidinesTumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristicsInhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in MedulloblastomaDovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer.Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cellsTherapeutic potential of antisense nucleic acid molecules.Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma.Recent advances in targeted therapy of human myelogenous leukaemia.c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarraysDesign, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agentsMET as a target for treatment of chest tumorsDifferentiated thyroid cancers: a comprehensive review of novel targeted therapies.Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study.Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway.Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas.Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells.Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications.A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.Utilization of fluorescence polarization and time resolved fluorescence resonance energy transfer assay formats for SAR studies: Src kinase as a model system.Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.FGFR4 as a Biomarker in Squamous Cell Cancers of Mouth and Oropharynx
P2860
Q24676378-BB9EC623-B856-4FD7-AF2C-08531D1ED175Q27320669-6AC5468A-DE8A-4897-AF2D-7C79AA1C75B0Q28378001-48638EC9-956F-42D9-92DE-9C172D9BA711Q28535045-B3CA8948-B8FB-4729-BAA3-D62427C2DD5BQ31016741-49A2AE1B-0FD2-4F86-84A2-E06D3088172FQ33835807-D19F2C37-AD1F-4ECA-A062-8545F5796E0CQ34041280-2B9B558E-D6A0-48E4-AED1-8CA6A481C9FEQ34398276-C89F09EA-466A-4D76-94C3-ACE77C70F2F5Q34991189-5C8E5BA5-245E-430D-A635-24816E624904Q35030845-3217FE2F-8EE1-45DA-8597-0EEBBE7079CDQ35207344-E5CEC168-3133-4398-ABF6-5B94A0E9BCF9Q35551938-3589F399-FE5E-4893-9037-F03207FFF5B3Q35570262-6857476E-8E14-4174-879C-78587584BDCEQ35864072-CD39623B-B8A5-4954-9085-1BA2E6D50475Q36135757-8BD82FC2-9D93-49E9-B516-F43F24B28E3DQ36318531-164FDEA6-3816-4212-945E-8E53EE5CA89CQ36609706-030E7BA8-EB6F-49DB-8B16-FF762CC22195Q36775982-3139F2B1-4F9F-479C-A1D0-9F839DACC0B8Q37232416-521F92DD-0E5D-4C00-84C9-A425AC1D138EQ37988566-6E14E571-3BBF-458A-8D5A-E5B83526F3E4Q38873050-AA73D946-085E-4232-88D3-C20FD62C0032Q38986019-DCCDB9AC-7295-42EE-AA3F-FF2338640BB4Q39315979-B6A40231-D18A-4824-B078-79AC715C0986Q40543731-EEB53B9D-BDF7-40AF-B32B-7ACA8EFDADA2Q42363585-A6DBA71B-043B-4E05-B985-50533C35852BQ45182199-F9D8A4A6-B993-4153-9E5C-B9357DB43962Q47576243-A6DAD25B-DC86-4765-87B3-E7E86D95D54AQ51988060-2CC1C756-A2D0-4F5C-B42D-3AFBCB0A0544Q54634447-1AAD9F3C-BC80-4C12-9A5A-2ED7D8406474Q57556242-74FF37E8-2159-448E-A980-87E26E9FDD8E
P2860
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@ast
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@en
type
label
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@ast
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@en
prefLabel
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@ast
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@en
P2860
P356
P1476
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
@en
P2093
A Douglas Laird
Julie M Cherrington
P2860
P356
10.1517/13543784.12.1.51
P407
P577
2003-01-01T00:00:00Z